Alkermes (ALKS) Revenue Growth (1y) (2011 - 2026)
Alkermes (ALKS) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 2.34% |
| 3 | Zoetis | 32.69 Bn | 30.75 Bn | 1.62 Bn | 2.91% |
| 4 | Takeda Pharmaceutical | 27.61 Bn | 23.55 Bn | 4.39 Bn | -11.85% |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | -1.62% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | 7.85% |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.53 Bn | 800.70 Mn | 42.25% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 14.92% |
| 10 | Alkermes | 8.80 Bn | 8.28 Bn | 331.33 Mn | 28.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.19% |
| Dec 31, 2025 | -10.57% |
| Sep 30, 2025 | 4.24% |
| Jun 30, 2025 | -2.12% |
| Mar 31, 2025 | -12.52% |
| Dec 31, 2024 | 13.91% |
| Sep 30, 2024 | -0.73% |
| Jun 30, 2024 | -35.35% |
| Mar 31, 2024 | 21.83% |
| Dec 31, 2023 | 23.89% |
| Sep 30, 2023 | 11,804.31% |
| Jun 30, 2023 | 19,193.66% |
| Mar 31, 2023 | 3.25% |
| Dec 31, 2022 | -6.10% |
| Sep 30, 2022 | -98.91% |
| Jun 30, 2022 | -98.95% |
| Mar 31, 2022 | 10.78% |
| Dec 31, 2021 | 15.88% |
| Sep 30, 2021 | 10.99% |
| Jun 30, 2021 | 22.70% |